Galenic development and effectiveness of gentamicin-sulphate 0.5% in a compounded formulation for the treatment of Hailey-Hailey disease

Authors

  • Álvaro González Gómez Pharmacy Department, Hospital Universitario 12 de Octubre, Madrid https://orcid.org/0009-0003-5506-7544
  • Veronica Monsalvez Hornubia Dermatology department, Hospital Universitario 12 de Octubre, Madrid
  • Lucia Alonso Perez Pharmacy Department, Hospital Universitario 12 de Octubre, Madrid
  • Jose Miguel Ferrari Piquero Pharmacy Department, Hospital Universitario 12 de Octubre, Madrid

DOI:

https://doi.org/10.60103/phc.v26.e857

Keywords:

Gentamicin sulphate; Drug compounding, Hailey Hailey disease

Abstract

Hailey-Hailey disease is a dermatological minority disease of genetic origin. It presents with the appearance of blistering lesions, especially in areas of friction and skin folds, such as the inguinal and axillary region and the neck. We present the case of a woman refractory to various immunosuppressive drugs. The Dermatology Department asked the Pharmacy Department to prepare a topical formulation of gentamicin for the management of the lesions. The Pharmacy Department prepared a 0.5% gentamicin sulfate ointment. After 4 weeks of treatment, total resolution of the submammary lesions and a decrease in the size of the axillary, antecubital and popliteal lesions were observed. At 3 months, all lesions were completely resolved, allowing the dose of apremilast to be reduced. At 6 months, the clinical response was maintained without adverse reactions.

Downloads

Download data is not yet available.

References

Engin B, Kutlubay Z, Çelik U, Serdaroğlu S, Tüzün Y. Hailey-Hailey disease: A fold (intertriginous) dermatosis. Clin Dermatol. 2015;33(4):452-5. doi: 10.1016/j.clindermatol.2015.04.006.

Yadav N, Madke B, Kar S, Prasad K, Gangane N. Hailey-Hailey disease. Indian Dermatol Online J. 2016;7(2):147-8. doi: 10.4103/2229-5178.178090.

Ben Lagha I, Ashack K, Khachemoune A. Hailey-Hailey Disease: An Update Review with a Focus on Treatment Data. Am J Clin Dermatol. 2020;21(1):49-68. doi: 10.1007/s40257-019-00477-z.

Guía de buenas prácticas de preparación de medicamentos en servicios de farmacia hospitalaria. Ministerio de Sanidad, Servicios Sociales e Igualdad. [Citado el 27/05/2024] Disponible en: https://www.sefh.es/sefhpdfs/GuiaBPP_JUNIO_2014_VF.pdf.

Pasmooij AMG. Topical Gentamicin for the Treatment of Genetic Skin Diseases. J Invest Dermatol. 2018;138(4):731-734. doi: 10.1016/j.jid.2017.12.008.

Kellermayer R, Szigeti R, Keeling KM, Bedekovics T, Bedwell DM. Aminoglycosides as potential pharmacogenetic agents in the treatment of Hailey-Hailey disease. J Invest Dermatol. 2006;126(1):229-31. doi: 10.1038/sj.jid.5700031.

Published

2024-10-16

How to Cite

González Gómez, Álvaro, Monsalvez Hornubia, V., Alonso Perez, L., & Ferrari Piquero, J. M. (2024). Galenic development and effectiveness of gentamicin-sulphate 0.5% in a compounded formulation for the treatment of Hailey-Hailey disease. Pharmaceutical Care España, 26. https://doi.org/10.60103/phc.v26.e857

Issue

Section

Casos clínicos